Hadas Barkay, PhD

Deutetrabenazine Reduces Severe Tardive Dyskinesia Movements in a 3-year Open-Label Extension Trial

Background: There are no established treatment guidelines for tardive dyskinesia (TD) based on movement severity. The 12-week ARM-TD and AIM-TD studies in TD patients with baseline Abnorm...

Joseph Bona , MD;

Amanda Wilhelm , PhD;

Hadas Barkay , PhD;

Nayla Chaijale , PhD;

Mark Forrest Gordon , MD;

10/18/2020

Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintenance in Patients With Tardive Dyskinesia

Background: Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly based on dyskinesia control and tolerability. This analysis compared the safety ...

Nayla Chaijale , PhD;

Alexander Send , PhD;

Juha-Matti Savola , MD, PhD;

Mark Forrest Gordon , MD;

Amanda Wilhelm , PhD;

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

10/08/2020

Randomized Withdrawal Study Design to Evaluate the Persistence of the Therapeutic Effect of Deutetrabenazine in the Treatment of Tardive Dyskinesia

Background: The long-term open-label extension study of rollover subjects (n=343) from the ARM-TD and AIM-TD trials evaluating the safety and efficacy of deutetrabenazine for the treatmen...

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Juha-Matti Savola , MD, PhD;

Mark Forrest Gordon , MD;

Maria Wieman , MPH;

Mat Davis , PhD;

Leslie Marinelli , BS;

11/22/2019

Analysis of AIMS Global Judgment Components (Items 8–10) in Patients With TD: Results From the ARM-TD and AIM-TD Studies

Background: Tardive dyskinesia (TD) is a debilitating, often-irreversible hyperkinetic movement disorder that impairs patients’ abilities to perform daily activities. Deutetrabenazine was...

Amanda Wilhelm , PhD;

Hadas Barkay , PhD;

Rolf T. Hansen , PhD;

Juha-Matti Savola , MD, PhD;

Maria Wieman , MPH;

Nicholas Gross , MS;

11/22/2019

Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline ...

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Juha-Matti Savola , MD, PhD;

Nicholas Gross , MS;

Stewart Factor , DO;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

11/22/2019

Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia

BACKGROUND: Deutetrabenazine, a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved by the FDA for treatment of tardive dyskinesia (TD) in adults. Dopamine-receptor ant...

Maria Wieman , MPH;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Juha-Matti Savola , MD, PhD;

Mark Forrest Gordon , MD;

Stewart Factor , DO;

11/22/2019